Prof Do Tat Cuong graduated from Hanoi Medical University in 1973. He is one of the first experts in kidney and organ transplantation in Vietnam in 1992. Throughout his career, he has been in charge of a number of important positions such as Vice Director of 103 Military Hospital; Director of Vinmec International Hospital. He has published nearly 100 studies on the international and domestic journals. He is also the author of medical textbooks. He reported at 30 International Science Conferences and being the chairman of 20 state and ministerial-level projects. By his dedicated and delightful contributions to the medical practices and research, he has been honored many prestige awards conferred by the Vietnam government like Ho Chi Minh Award in Organ Transplantation; State Award; People’s Physician; Merit of the Ministry of Health; Merit from the Prime Minister of Vietnam; The Exclusive Patent on the Emergency Tracheostomy Percutaneous set.
Backgrounds: Tacrolimus is one of the basic immunosuppressive drugs for treating post-transplant renal patients. Two main challenges associated with the tacrolimus are choosing the correct starting dose and making adequate dose adjustments to compensate for changing the time of pharmacokinetics after transplantation. Herein, we study on individualized tacrolimus in patients with kidney transplantation based on the determination of CYP3A5 genotypes.
Methods: In this study, 40 patients with kidney transplantation and 200 healthy persons were selected. The CYP3A5 sequence was determined to find rs6986 polymorphism (A> G) region.
Results: We recognized that at least one allele CYP3A5*1 existing in 23 patients and 120 heathy people occupying to 57.5% and 60%, respectively. This ratio is quite high in Vietnamese. Furthermore, our finding indicated that the patients with one allele CYP3A5*1 require 1.3 to 2 times higher initial tacrolimus dose to reduce the time of reaching the trough concentration compared to usual therapeutic dose (0.2 to 0.3mg/kg/day).
Conclusions: Frequency of allele CYP3A5*1 was determined in both healthy people and patients. Initial tacrolimus dose was determined for patients with each genotype. CYP3A5 gene testing should be performed on patients with kidney transplantation to individualize the tacrolimus dose and reduce the time of reaching the trough concentration after transplantation.